Exencial Wealth Advisors LLC Sells 3,207 Shares of Edwards Lifesciences Co. (NYSE:EW)

Exencial Wealth Advisors LLC reduced its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 152,813 shares of the medical research company’s stock after selling 3,207 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $11,313,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the fourth quarter worth $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences during the 4th quarter worth $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,739 shares of company stock valued at $2,799,104. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of a number of research reports. The Goldman Sachs Group boosted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Citigroup raised their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Trading Down 0.3 %

Shares of EW stock opened at $71.37 on Tuesday. The business has a 50-day moving average price of $72.58 and a two-hundred day moving average price of $70.32. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market cap of $42.09 billion, a P/E ratio of 10.24, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.